CarboExpert Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
6
CarboExpert General Information
Description
Operator of a bio-venture company intended to provide customized resources for product efficacy. The company supplies materials customized based on enzyme engineering, carbohydrate engineering, and microbial metabolism control technologies, enabling pharmaceuticals, cosmetics, and food industries to improve their operational efficiency.
Contact Information
Website
carboexpert.co.krCorporate Office
- 34134 Room 705, Industry-Academia-Research Education Research Center
- Chungnam National University, 99 Daehak-ro, Yuseong-gu
- Daejeon, 34134
- South Korea
Corporate Office
- 34134 Room 705, Industry-Academia-Research Education Research Center
- Chungnam National University, 99 Daehak-ro, Yuseong-gu
- Daejeon, 34134
- South Korea
CarboExpert Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 3. Later Stage VC (Series A) | 31-Oct-2021 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-May-2019 | Completed | Generating Revenue | |||
| 1. Seed Round | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
CarboExpert Patents
CarboExpert Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025143932-A1 | Pharmaceutical composition for preventing or treating eosinophilia or eosinophilic inflammatory diseases, comprising inotodiol or prodrug thereof | Inactive | 29-Dec-2023 | ||
| AU-2024265857-A1 | Pharmaceutical formulation comprising lanosterol, derivative thereof, and cyclodextrin | Pending | 02-May-2023 | ||
| EP-4706685-A1 | Pharmaceutical formulation comprising lanosterol, derivative thereof, and cyclodextrin | Pending | 02-May-2023 | ||
| EP-4706685-A4 | Pharmaceutical formulation comprising lanosterol, derivative thereof, and cyclodextrin | Pending | 02-May-2023 | ||
| US-20260295073-A1 | Pharmaceutical formulation comprising lanosterol, derivative thereof, and cyclodextrin | Pending | 02-May-2023 | A61K47/6951 |
CarboExpert Signals
CarboExpert Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| A-Stone Ventures | Venture Capital | Minority | ||
| Honest Ventures | Venture Capital | Minority | ||
| KC Ventures | Venture Capital | Minority | ||
| Root Ventures (South Korea) | Venture Capital | Minority | ||
| Tech Incubator Program for Startup | Accelerator/Incubator |
CarboExpert FAQs
-
When was CarboExpert founded?
CarboExpert was founded in 2015.
-
Where is CarboExpert headquartered?
CarboExpert is headquartered in Daejeon, South Korea.
-
What is the size of CarboExpert?
CarboExpert has 10 total employees.
-
What industry is CarboExpert in?
CarboExpert’s primary industry is Biotechnology.
-
Is CarboExpert a private or public company?
CarboExpert is a Private company.
-
What is CarboExpert’s current revenue?
The current revenue for CarboExpert is .
-
Who are CarboExpert’s investors?
A-Stone Ventures, Honest Ventures, KC Ventures, Root Ventures (South Korea), and Tech Incubator Program for Startup are 5 of 6 investors who have invested in CarboExpert.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process